AnaptysBio (ANAB) Q4 2025 earnings summary

Executive summary

• Announced intent to spin off biopharma operations into First Tracks Biotherapeutics, targeting Q2 2026, to create two independent public companies with distinct focuses.

• Jemperli royalties and milestones drove significant revenue growth, with strong commercial performance and a $75 million milestone received in Dec. 2025.

• Advanced clinical pipeline with ongoing trials for ANB033 in celiac disease and eosinophilic esophagitis, and presented Phase 2b data for rosnilimab in rheumatoid arthritis.

Financial highlights

• Cash, cash equivalents, and investments totaled $311.6 million as of Dec. 31, 2025, down from $420.8 million a year prior, reflecting operating expenses and share repurchases.

• Collaboration revenue was $108.2 million for Q4 2025 and $234.6 million for FY 2025, up from $43.1 million and $91.3 million in 2024, driven by Jemperli milestones and royalties.

• Net income for Q4 2025 was $49.6 million ($1.79 per share), while FY 2025 saw a net loss of $13.2 million ($0.46 per share), a significant improvement from a $145.2 million loss in FY 2024.

• Repurchased 3,444,079 shares (11.2% of shares outstanding) for $68.6 million as of Dec. 31, 2025.

Outlook and guidance

• Spin-off of biopharma operations expected in Q2 2026, with First Tracks Biotherapeutics launching with sufficient capital for key milestones.

• Anticipate >$390 million in annualized Jemperli royalties at GSK's peak sales guidance of >$2.7 billion as early as 2029.

• Top-line Phase 1b data for ANB033 in celiac disease expected Q4 2026; eosinophilic esophagitis data anticipated in 2027.

• Full paydown of $600 million non-recourse debt monetization expected by end of Q2 2027.